# Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response

> **NCT00640250** · PHASE2 · COMPLETED · sponsor: **Allerderm** · enrollment: 48 (actual)

## Conditions studied

- Contact Dermatitis

## Interventions

- **BIOLOGICAL:** T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens

## Key facts

- **NCT ID:** NCT00640250
- **Lead sponsor:** Allerderm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-03
- **Final completion:** 2009-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640250, "Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00640250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*